GlassScriptPhysician profile
Keri J Mcfarlane
NPI 1588688998
$1,927.03
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $542 · 2021: $582 · 2022: $607 · 2023: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $195.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $300.24 | 2020-2023 | Emgality, Jardiance |
| Novo Nordisk INC | $199.06 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $180.36 | 2022-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $115.74 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $101.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $90.24 | 2020-2021 | |
| Genzyme Corporation | $84.51 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.84 | 2022-2023 | Xifaxan |
| Amgen INC. | $74.04 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.23 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $61.10 | 2022-2023 | Farxiga |
| Neurelis, INC. | $61.04 | 2020-2021 | |
| Allergan, INC. | $52.30 | 2020 | |
| Abbvie INC. | $49.62 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $48.06 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $47.48 | 2020-2021 | |
| Pfizer INC. | $37.57 | 2023 | |
| Csl Behring | $30.68 | 2020 | |
| Upsher-Smith Laboratories LLC | $29.23 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.90 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.30 | 2021 | |
| Merck Sharp & Dohme LLC | $25.11 | 2020 | |
| Horizon Therapeutics Plc | $23.59 | 2020 | |
| Ucb, INC. | $23.18 | 2021 | |
| Daiichi Sankyo INC. | $20.47 | 2020 | |
| Lundbeck LLC | $19.74 | 2021 | |
| Dexcom, INC. | $19.56 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $15.03 | 2021 | |
| Medtronic, INC. | $13.55 | 2021 | |
| Zyla Life Sciences, INC. | $12.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keri Mcfarlane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.